Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 15/20 | 0.58 |
| ▸ | EGFR | P00533 | 4/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13523340 | 0.82 | KDM1A (0.58) | KDM1AEGFRGAKKDR | |
| SCHEMBL19933282 | 0.81 | ENPP1 (0.53) | EGFRGAKKDRFLT1 | |
| SCHEMBL29736163 | 0.81 | KDM1A (0.57) | KDM1AEGFRGAKKDR | |
| SCHEMBL2221126 | 0.81 | KDM1A (0.57) | KDM1AEGFRGAKKDR | |
| SCHEMBL163465 | 0.81 | ENPP1 (0.71) | KDM1AEGFRGAKKDRFLT1 | |
| SCHEMBL1983663 | 0.81 | KDM1A (0.64) | KDM1AEGFRGAKKDR | |
| SCHEMBL1985866 | 0.81 | KDM1A (0.57) | KDM1AEGFRGAKKDR | |
| SCHEMBL29478510 | 0.81 | ENPP1 (0.71) | KDM1AEGFRGAKKDRFLT1 | |
| SCHEMBL471137 | 0.81 | KDM1A (0.57) | KDM1AEGFRGAKKDRFLT1 | |
| Hydrochloric Acid SCHEMBL8307436 | 0.79 | ENPP1 (0.69) | KDM1AEGFRGAKKDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139868-B1 | PROCESS FOR PREPARATION OF ERLOTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | CIPLA LTD (IN) | 2015-07-29 | — | — | EP | claimed |
| US-8642758-B2 | Process for preparation of erlotinib and its pharmaceutically acceptable salts | CIPLA LIMITED (IN) | 2014-02-04 | — | — | US | claimed |
| US-20100094004-A1 | Process for Preparation of Erlotinib and its Pharmaceutically Acceptable Salts | CIPLA LIMITED (IN) | 2010-04-15 | — | — | US | claimed |
| EP-2139868-A2 | PROCESS FOR PREPARATION OF ERLOTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | Cipla Limited (IN) | 2010-01-06 | — | — | EP | claimed |
| WO-2008122776-A2 | PROCESS FOR PREPARATION OF ERLOTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | CIPLA LIMITED (IN) | 2008-10-16 | — | — | WO | claimed |
| EP-2139868-B1 | PROCESS FOR PREPARATION OF ERLOTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | CIPLA LTD (IN) | 2015-07-29 | — | — | EP | disclosed |
| US-20140194624-A1 | Process for Preparation of Erlotinib and its Pharmaceutically Acceptable Salts | CIPLA LIMITED (IN) | 2014-07-10 | — | — | US | disclosed |
| US-8642758-B2 | Process for preparation of erlotinib and its pharmaceutically acceptable salts | CIPLA LIMITED (IN) | 2014-02-04 | — | — | US | disclosed |
| US-20100094004-A1 | Process for Preparation of Erlotinib and its Pharmaceutically Acceptable Salts | CIPLA LIMITED (IN) | 2010-04-15 | — | — | US | disclosed |
| EP-2139868-A2 | PROCESS FOR PREPARATION OF ERLOTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | Cipla Limited (IN) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008122776-A2 | PROCESS FOR PREPARATION OF ERLOTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | CIPLA LIMITED (IN) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194624-A1 | Process for Preparation of Erlotinib and its Pharmaceutically Acceptable Salts | ABL1, EGFR, KRAS | KDM1A 3703/4885EGFR 2/4885GAK 2303/4885 |
| US-20100094004-A1 | Process for Preparation of Erlotinib and its Pharmaceutically Acceptable Salts | ABL1, EGFR, KRAS | KDM1A 3534/4885EGFR 2/4885GAK 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.